echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > "Thiazolidinedione" in combination with second-line oral hypoglycemic therapy reduces the risk of acute exacerbation in patients with advanced diabetes mellitus with COPD

    "Thiazolidinedione" in combination with second-line oral hypoglycemic therapy reduces the risk of acute exacerbation in patients with advanced diabetes mellitus with COPD

    • Last Update: 2022-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Multiple comorbidities are common in type 2 diabetes mellitus (T2DM), and only about 14% of patients may not have other comorbidities


    American Diabetes Association (ADA) guidelines recommend metformin (if noncontraindicated and tolerable) as the initial oral antiglycemic drug (OAD) of choice for the treatment of T2DM


    It is unclear whether strict glycemic control in patients with COPD-T2DM improves coprogenic prognosis, but according to previous studies, poor glycemic control can exacerbate coprhage severity and clinical course


    Investigators conducted cohort-based case-control studies using data from the Taiwan Provincial Health Insurance Research Database


    In COPD-T2DM patients, 3355 patients with AECOPD and 13420 matching controls were selected


    Relationship between OAD dual-drug therapy and AECOPD risk in patients with type 2 diabetes mellitus with COPD (n=12916)

    Relationship between triple drug treatment of OAD and AECOPD risk in patients with type 2 diabetes mellitus with COPD (n=3859)

    In simple terms, the results of this analysis show that in patients receiving a combination of two and three drugs for OAD, the addition of TZD reduces the risk of


    Taken together, these results suggest that in patients with COPD-T2DM, combination therapy with TZDs is associated with a reduced risk of AECOPD, especially in people


    References: 1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.